Ocular Therapeutix submits NDA for Dextenza to treat postop ocular pain

Ocular Therapeutix submitted a new drug application to the FDA for Dextenza to treat ocular pain after ophthalmic surgery, according to a press release. “This represents Ocular Therapeutix’s first NDA filing with the FDA and is an important development milestone as we advance our broad-based programs for the treatment of ocular diseases and conditions through clinical development and potential commercialization pending FDA approval,” Amar Sawhney, PhD, president, CEO and chairman of Ocular Therapeutix, said in the release.